ARTICLE | Clinical News
Ironwood, Allergan start Phase IIIb of Linzess in IBS-C
July 20, 2018 4:13 PM UTC
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) began a double-blind, placebo-controlled, U.S. Phase IIIb trial to evaluate 290 µg Linzess linaclotide once daily in about 600 patients with irritable bowel syndrome with constipation (IBS-C).
The primary endpoint is the change from baseline in abdominal score based on daily patient assessments of abdominal bloating, discomfort and pain on an 11-point scale...
BCIQ Target Profiles